Overall, our data suggest that VEXAS patients exhibit an upregulation of IL-1β and IL-18 signatures at the transcriptional level suggesting inflammasome activation, and TNF-α family and NFκB signaling that could mediate cell death and inflammation. The gene discussed is TNF; the disease is VEXAS syndrome.